Literature DB >> 31782591

Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples.

Jermaine D Jones1, Elliana Sherwin1, Suky Martinez1,2,3, Sandra D Comer1.   

Abstract

BACKGROUND AND
OBJECTIVE: This retrospective analysis of data from heroin users screening for clinical research, sought to determine if more naloxone is needed to precipitate opioid withdrawal among those who regularly use heroin with fentanyl, as opposed to those who use heroin without fentanyl.
METHODS: Over the course of three to five screening visits, participants completed assessments of drug use, along with urine toxicology tests at each visit. To test for opioid dependence, 29 participants completed a modified Wang test (score: 0-150) during which an intramuscular dose of naloxone (0.2-0.4 mg) was administered and the severity of withdrawal was quantified.
RESULTS: The severity of opioid withdrawal was compared between individuals whose urine toxicology regularly tested positive for fentanyl (N = 15), and those only positive for other opioids (N = 14). No significant differences were found in demographic or drug use between the fentanyl-positive (mean: age 41.1 years, 9.1 bags heroin/d) and fentanyl-negative (42.0 years, 10.0 bags heroin/d) groups. Intramuscular naloxone-precipitated robust withdrawal in both samples (P < .01) with no significant difference (P = .8) in the severity (fentanyl positive [100.6 ± 13.4]; fentanyl negative [82.7 ± 9.6]). CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: These data suggest that a standard naloxone dose can be equally effective at precipitating withdrawal in individuals using heroin with fentanyl compared to heroin without fentanyl. These data contribute to our understanding of how naloxone antagonizes the effects of fentanyl and may have significant implications for the clinical laboratory and opioid overdose. A prospective clinical laboratory study with the proper opioid maintenance controls is needed to provide a more definitive finding. (Am J Addict 2019;00:00-00).
© 2019 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31782591      PMCID: PMC6927546          DOI: 10.1111/ajad.12979

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  12 in total

1.  Opioid abuse in the United States and Department of Health and Human Services actions to address opioid-drug-related overdoses and deaths.

Authors: 
Journal:  J Pain Palliat Care Pharmacother       Date:  2015-06

Review 2.  A review: Fentanyl and non-pharmaceutical fentanyls.

Authors:  Joji Suzuki; Saria El-Haddad
Journal:  Drug Alcohol Depend       Date:  2016-12-16       Impact factor: 4.492

Review 3.  Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review.

Authors:  Patil Armenian; Kathy T Vo; Jill Barr-Walker; Kara L Lynch
Journal:  Neuropharmacology       Date:  2017-10-14       Impact factor: 5.250

4.  Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.

Authors:  Nadia Fairbairn; Phillip O Coffin; Alexander Y Walley
Journal:  Int J Drug Policy       Date:  2017-07-04

5.  Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.

Authors:  Philip A Krieter; C Nora Chiang; Shwe Gyaw; David J McCann
Journal:  J Clin Pharmacol       Date:  2019-03-12       Impact factor: 3.126

6.  Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths - 27 States, 2013-2014.

Authors:  R Matthew Gladden; Pedro Martinez; Puja Seth
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-08-26       Impact factor: 17.586

7.  Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria.

Authors:  T A Kosten; L K Jacobsen; T R Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  1989       Impact factor: 3.829

8.  Mechanism of opioid-induced pupillary effects.

Authors:  Merlin D Larson
Journal:  Clin Neurophysiol       Date:  2008-04-07       Impact factor: 3.708

9.  The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.

Authors:  Jermaine D Jones; Adam Bisaga; Verena E Metz; Jeanne M Manubay; Shanthi Mogali; Roberto Ciccocioppo; Gabriela Madera; Molly Doernberg; Sandra D Comer
Journal:  J Psychoactive Drugs       Date:  2018-09-11

10.  Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region - United States, 2006-2015.

Authors:  Julie K O'Donnell; R Matthew Gladden; Puja Seth
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-01       Impact factor: 17.586

View more
  1 in total

1.  Functional connectivity of posterior cingulate gyrus in heroin dependents treated by methadone maintenance and protracted abstinence measures: an event-related fMRI study.

Authors:  Xuan Wei; Jiajie Chen; Jia Zhu; Qiang Li; Wei Li; Wei Wang
Journal:  Brain Imaging Behav       Date:  2021-01-27       Impact factor: 3.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.